Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 96Rectal Neoplasms 45Colorectal Neoplasms 45Carcinoma, Non-Small-Cell Lung 31Esophageal Neoplasms 28Esophageal Squamous Cell Carcinoma 24Stomach Neoplasms 22Lung Neoplasms 20Pancreatic Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Colonic Neoplasms 18Neoplasms 16Sarcoma 15Adenocarcinoma Of Esophagus 15Ovarian Neoplasms 14Neoplasm Metastasis 14Head and Neck Neoplasms 14Carcinoma, Hepatocellular 14Prostatic Neoplasms 13Urinary Bladder Neoplasms 12Uterine Cervical Neoplasms 10Inflammatory Breast Neoplasms 9Fallopian Tube Neoplasms 9Osteosarcoma 8Central Nervous System Neoplasms 8Carcinoma, Intraductal, Noninfiltrating 8Kidney Neoplasms 7Carcinoma, Ovarian Epithelial 7Recurrence 6Multiple Myeloma 6

Interventions

Trastuzumab 33pertuzumab 18Docetaxel 16pyrotinib 15Paclitaxel 7Capecitabine 6tucatinib 5Carboplatin 5Ado-Trastuzumab Emtansine 4trastuzumab deruxtecan 3neratinib 3atezolizumab 2Protons 2Fulvestrant 2pegfilgrastim 1palbociclib 1margetuximab 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1Taxoids 1Neoadjuvant Therapy 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Injections 1Hospital Information Systems 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Neoadjuvant Therapy × Clear all
NCT06832904 2025-02-18

Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
33 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡